CNBC : Would you invest with Steve Cohen?


Would you invest with Steve Cohen?
Steve Cohen is planning to launch a $20 billion hedge fund — and many institutional investors are planning to steer clear of it.
Cohen has been managing his own fortune at Point72 Asset Management, the family office he created in 2014 after his hedge fund firm, SAC Capital Advisors, pleaded guilty to insider-trading charges in the largest securities fraud case ever brought against a hedge fund. As part of the settlement, Cohen closed SAC and paid $1.8 billion in fines. In 2016, the Securities and Exchange Commission announced that Cohen would be barred from managing outside money until January 2018 to settle separate charges that he failed to supervise a former portfolio manager who had engaged in insider trading at SAC.
Cohen himself was never charged with insider trading, and the brevity of his ban sparked immediate speculation about when, not if, he would open a hedge fund after the order expired — not least of all because SAC delivered astonishing annual returns of 29 percent for 21 years. Sure enough, a Wall Street Journal report in late May said Cohen is planning to launch a new hedge fund open to outsiders as early as next year.
More from Institutional Investor:
Private capital managers are charging higher fees
Fund managers warn of European property bubble
Carnegie CIO goes it alone
Cohen may have to rely on a network of rich hedge fund managers and friends, as well as his own money, to get it off the ground, as institutional investors — including corporate and public pension funds, endowments, and foundations — are not likely to pony up money. Of course, Cohen may not need institutional money to reach $20 billion, which is more money than he oversaw at SAC, but he may miss the imprimatur that managing money for a nationally known pension fund or an Ivy League endowment can lend. A representative for Cohen declined to comment.
Institutions won't necessarily stay away because they are skeptical of Cohen's ability to generate returns. Rather, they fear bad publicity. Even talking on the record about possibly investing in Cohen's hedge fund comes with some reputational risk. Almost all of the institutional investors interviewed for this story agreed to speak only on condition of anonymity.
One chief investment officer of a corporate pension plan expects few, if any, pension plans to invest with Cohen. "I can't see anybody with a corporate plan doing something like this. Sooner or later, you have to report to the board," says the CIO. "There's infinite career risk for the CIO who tries to go down that path."
The CIO of a large U.S. public pension fund says underfunded plans could clearly use Cohen's returns, but trustees wouldn't want to expose themselves to the potential bad press. "It's hard to justify the headline risk, which could suck up an enormous amount of time and emotional energy."
Some industry watchers think sovereign wealth funds could be a big source of funds for Cohen, as many are not subject to the kinds of transparency requirements that pensions must adhere to. Endowments, too, could invest with Cohen, as they generally are more secretive about the underlying managers in their portfolios and have historically invested in asset classes and firms that are off the beaten path.
At the same time, endowments are facing political and governance issues, such as calls for divestment from fossil fuels. "It wouldn't look great to get out of something like Exxon stock and then plow money into Cohen, whose former firm was the poster child for bad hedge fund behavior," notes one executive at an asset management firm.
Others have reservations for more traditional reasons. An active manager with $20 billion is too big to be able to outperform in the current market environment, says Jim Dunn, CEO and CIO of Verger Capital Management, which manages money for endowments, including that of Wake Forest University. "There aren't that many good ideas out there," he explains. "It's going to be hard to put that money to work given how low rates are and given fund flows from passive managers that are driving everything up."
Cohen has taken steps to make even his family office more institutional. He has invested in a range of businesses, including crowdsourced quantitative manager Quantopian; spent heavily on compliance for Point72; and brought in a new team with gold-plated pedigrees, including McKinsey executive Doug Haynes, Point72's president.
Though Cohen's reputation may have been tarnished by his regulatory woes, his status as a hedge fund legend remains firmly intact. Even outside finance, the name Point72 evokes prestige. And even if institutional investors give Cohen's new fund a pass, there is one group of potential investors who may not be able to resist it. "He'll get big checks from hedge fund managers," says a former hedge fund executive. "It's their way to give a giant f– you to regulators."

TechCrunch : HERE’s Real-Time Traffic pools live data from Audi, BMW and Mercede

HERE’s Real-Time Traffic pools live data from Audi, BMW and Mercedes-Benz cars

Mapping expert HERE is launching a Real-Time Traffic service that pulls aggregated data from sensors in Audi, BMW and Mercedes-Benz vehicles that are actually out driving the road, making it the first commercial traffic service of its kind that collects real-time information from vehicles from competing carmakers, according to HERE.
The car companies involved are actually all part owners of HERE, however, after the mapping business was spun out of Nokia in 2015 and sold to the competing automakers as a joint venture. The HERE Real-Time Service is available to any customers across any industry, however, and boasts big improvements in features including traffic flow data, with a reach that extends to over 60 countries.
In over 30 of the countries on that list, HERE also offers Traffic Safety Warning information, which will identify incidents on the road, as measured by hard-braking data. This allows real-time notifications to vehicles that could potentially prevent the worsening of these accidents.

HERE is also in the process of adding more commercial vehicles as data sources for the Real-Time Traffic function, with “millions” of active vehicles in terms of consumer Audi, BMW and Mercedes-Benz vehicles on the road already.
Clients for the service could include autonomous car technology companies, but also current Advanced Driver Assistance Systems (ADAS) as well as ride-hailing companies, urban transit authorities, city planners and logistics providers, to name a few.

>>> USGapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • FH -19.1%, USNA -14%, AKAM -6.7%, UHS -6.7%, WYNN -4.4%, CHGG-4.2%, SIX -4.1%, USG -3.8%, CSL -3.6%, AMGN -2.9%, HA -2.9%, DHI-2.7%, ANGI -2.7%, LN -2.6%, SFLY -2.3%, BKU -2%, F -2%, ESRX -1.9%,RHI -1.8%, JNPR -1.5%, HT -1.5%, IR -1.4%, AOS -0.9%, .
Other news:
  • OEC -6.8% (offers prelim Q2 results, prices secondary offering by selling shareholders of 10 mln shares of common stock at $21.85)
  • MC -4.3% (prices 6 mln shares of common stock at $42.00 per share)
  • APRN -3.3% (details several changes to executive leadership team; Co-Founder and Chief Operating Officer Matthew Wadiak stepping down from role)
  • PLX -2.6% (enters exchange agreement of $9 mln of its 4.50% Senior Convertible Notes due 2018 for $8.55 million aggregate principal amount of newly issued 4.50% Senior Convertible Notes due 2022)
  • MLCO -2% (WYNN sympathy)
  • LVS -1.4% (WYNN sympathy)
Analyst comments:
  • DISH -1.7% (upgraded to Overweight from Underweight at Morgan Stanley)
  • LAMR -1.4% (downgraded to Market Perform from Outperform at Wells Fargo)
  • PWR -1.2% (downgraded to Neutral at Robert Baird)
  • JBLU -1.1% (downgraded to Neutral from Buy at Buckingham Research)
  • ZTS -0.8% (downgraded last night to Hold from Buy at Deutsche Bank)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:
  • OPHT +11.4%, AMD +9.4%, X +7.6%, SFS +7.4%, EXAS +7.2%, RCKY+3.8%, TRN +3.6%, RES +3.6%, SLAB +3.5%, SN +3.5%, ZION +3%, BGCP+2.8%, T +2.7%, CMG +2.6%, WES +2.1%, STM +1.9%, BA +1.7%, LUV+1.7%, CMRE +1.6%, BAX +1.5%, APH +1.5%, TSS +1.4%, NYCB +1.4%,IVTY +1.3%, LEA +1%
M&A news:
  • IRBT +20.6%, (to acquire privately-held Robopolis SAS for $141 mln )
  • GUID +2.8% (o be acquired by OpenText (OTEX) for $7.10 per share)
  • SNI +1.3% (Viacom (VIAB) said to be willing to make an all-cash offer for Scripps, according to Reuters)
  • SHPG +1% (renewed M&A speculation)
Other news:
  • TTPH +28.6% (Tetraphase Pharmaceuticals announces top-line results from IGNITE4, the Company's phase 3 clinical trial evaluating the efficacy and safety of twice-daily intravenous (IV) eravacycline compared to meropenem for the treatment of patients with complicated intra-abdominal infections)
  • ARGS +25% (announces publication of immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection in the Journal of AIDS Research and Human Retroviruses)
  • ETRM +19.3% (enters into Collaboration Agreement with Galvani Bioelectronics Limited)
  • MDGS +5.1% (distribution agreement in Switzerland and Liechtenstein with ADMEDICS)
  • BLRX +2.2% (announces that BVF Partners will make an additional, direct investment of $9.6 million in BioLineRx, increasing its economic interest in the Company to 24.9%)
  • EVGN +2.2% (enter into multiyear collaboration with DuPont)
  • NVDA +1.4% (in sympathy with AMD)
Analyst comments:
  • OCUL +3.7% (initiated with a Buy at H.C. Wainwright)
  • EA +2% (upgraded to Buy from Neutral at BofA/Merrill)
  • DSW +1.9% (upgraded to Outperform from Neutral at Wedbush)

>>> US Early premarket gappers

Early premarket gappers
Gapping up:
  • TTPH +35.9%, IRBT +20.6%, ETRM +18.4%, OPHT +11.4%, AMD +9.4%, X+7.6%, SFS +7.4%, EXAS +7.2%, RCKY +3.8%, TRN +3.6%, RES +3.6%,SLAB +3.5%, SN +3.5%, MOS +3.2%, ZION +3%, T +2.7%, CMG +2.6%,CMG +2.6%, WES +2.1%, STM +1.9%, BA +1.7%, LUV +1.7%, CMRE+1.6%, NVDA +1.5%, EA +1.5%, BAX +1.5%, QCOM +1.4%, TSS +1.4%,NYCB +1.4%, WLL +1.3%, IVTY +1.3%, POT +1.2%, LEA +1%, RIG +0.9%,MU +0.9%, WOR +0.8%, CIGI +0.8%, HES +0.8%, WM +0.8%, CMC +0.7%,RETA +0.6%, TXN +0.6%, KO +0.5%
Gapping down:
  • FH -19.1%, USNA -14%, DRYS -11.3%, CGEN -11.1%, OEC -7.2%, OEC-7.2%, AKAM -6.7%, UHS -6.7%, APRN -5.3%, MC -4.5%, WYNN -4.4%,CHGG -4.2%, SIX -4.1%, CSL -3.6%, AMGN -2.9%, HA -2.9%, DHI -2.7%,PLX -2.6%, SFLY -2.3%, MLCO -2%, BKU -2%, F -2%, ESRX -1.9%, RHI-1.8%, LVS -1.7%, JNPR -1.5%, HT -1.5%, IR -1.4%, AOS -0.9%, ZTS-0.8%, FLIR -0.8%, DLB -0.7%, ANTM -0.5%

Market report: Chatter over bid for Shire puts suitors in frame

Market report: Chatter over bid for Shire puts suitors in frame

The City rumour mill was in full flow today as deal-hungry traders suggested drug-maker Shire was back in play.
Gossips said some of the biggest drugs firms in Europe and the US have hired advisers ahead of a possible tilt at the Dublin-based company.
They added that Shire, fearing lowball bids, had hired defence advisers.
Earlier this month, the FTSE 100 company’s chief executive Flemming Ornskov hinted that investors were valuing Shire too low after a 10% fall from the share price this year.
He pointed to the healthy pipeline of drugs, including for ADHD and haemophilia, which came as part of the £22 billion acquisition of Baxalta.
Shire accepted a £32 billion cash and shares bid in 2014 from US rival AbbVie worth around 5300p per share before a clampdown on tax inversion deals scuppered the takeover.
The shares now languish at 4284.5p, up another 63.31p, or 1.5%, today after gaining ground yesterday, valuing the firm at £39 billion. Shire declined to comment on the speculation.

>>> Boeing beats by $0.24, misses on revs; raises FY17 EPS above consensus, reaf

Boeing beats by $0.24, misses on revs; raises FY17 EPS above consensus, reaffirms FY17 revs guidance
  • Reports Q2 (Jun) earnings of $2.55 per share, excluding non-recurring items, $0.24 better than the Capital IQ Consensus of $2.31; revenues fell 8.1% year/year to $22.74 bln vs the $22.97 bln Capital IQ Consensus.
  • Co issues guidance for FY17, raises EPS to $9.80-10.00 from $9.20-9.40, excluding non-recurring items, vs. $9.40 Capital IQ Consensus; reaffirms FY17 revs of $90.5-92.5 bln vs. $92 bln Capital IQ Consensus Estimate. Operating cash flow guidance increased by $1.5 billion to $12.25 billion on solid execution and a cash tax benefit from accelerating pension funding in the third quarter of 2017. Additionally, capital expenditures guidance decreased by $300 million to $2.0 billion. reflecting planned production rates and timing of commercial and defense aircraft deliveries. Backlog grew to $482 billion, including $27 billion of net orders during the quarter

>>> NextEra Energy beats by $0.10, reports revs in-line; reaffirms FY17 EPS guid

NextEra Energy beats by $0.10, reports revs in-line; reaffirms FY17 EPS guidance; reaffirms FY18 EPS guidance
  • Reports Q2 (Jun) earnings of $1.86 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus of $1.76; revenues rose 15.4% year/year to $4.4 bln vs the $4.44 bln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees EPS of $6.35-6.85, excluding non-recurring items, vs. $6.71 Capital IQ Consensus Estimate.
  • Co reaffirms guidance for FY18, sees EPS of $6.80-7.30, excluding non-recurring items, vs. $7.22 Capital IQ Consensus Estimate.
  • Reaffirms EPS expectations for FY20 of $7.85-8.45 vs $6.19 in FY16.
    "NextEra Energy achieved strong second-quarter results, while continuing to deliver on our overall objectives for 2017," said Jim Robo, chairman and chief executive officer of NextEra Energy. "NextEra Energy's second-quarter adjusted earnings per share increased more than 11 percent, primarily driven by new investments at both FPL and NextEra Energy Resources. During the quarter, FPL executed on its innovative and cost-effective approach of advancing affordable, reliable clean energy infrastructure across Florida. In line with this strategy, construction is underway on eight 74.5-megawatt solar energy centers across FPL's service territory, and construction remains on track at our state-of-the-art, natural gas-fueled Okeechobee Clean Energy Center. FPL also is moving forward with plans to modernize the Lauderdale Plant in Dania Beach by building a highly fuel-efficient energy center at the site. By continuing to execute on major capital initiatives to deliver on our outstanding customer value proposition, FPL grew regulatory capital employed by more than 10 percent versus the comparable period. At NextEra Energy Resources, we are well-positioned to capitalize on one of the best environments for renewables development in our history and remain encouraged by the improvement in costs, efficiencies and advancements in battery storage toward providing customers with firm renewable power. The Energy Resources team built on the origination success with which we started the year, signing more than 631 megawatts of additional wind and solar power purchase agreements and adding an additional 200 megawatts to our repowering backlog. Overall, we believe we have one of the best organic growth opportunity sets in our industry, and, as I've said previously, we will be disappointed if we are not able to deliver financial results at or near the top of our 6 to 8 percent adjusted earnings per share growth range through 2020."

>>> General Dynamics beats by $0.02, misses on revs; guides FY17 EPS in-line

General Dynamics beats by $0.02, misses on revs; guides FY17 EPS in-line
  • Reports Q2 (Jun) earnings of $2.45 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $2.43; revenues fell 1.3% year/year to $7.67 bln vs the $7.76 bln Capital IQ Consensus.
    • General Dynamics' total backlog at the end of second-quarter 2017 was $58.6 billion. There was order activity across the Gulfstream product portfolio and strong demand for defense products, including another quarter of a book-to-bill ratio (orders divided by revenue) greater than one-to-one in the Information Systems and Technology group. The estimated potential contract value, representing management's estimate of value in unfunded indefinite delivery, indefinite quantity (IDIQ) contracts and unexercised options, was $24.4 billion. Total potential contract value, the sum of all backlog components, was $83 billion at the end of the quarter.
  • Co raises guidance for FY17, sees EPS of $9.70-9.75 (Prior $9.50-9.55), excluding non-recurring items, vs. $9.80 Capital IQ Consensus Estimate.
    • Briefing.com Note: It is not clear if the guidance is comparable to the estimate as there appears to be one outlier of $10.74.